ArticleCancers2022

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer.

Xuan Ge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.